SLC20A1-DT: A Promising Drug Target Or Biomarker (G400999)

Target Name: SLC20A1-DT

NCBI ID: G400999

SLC20A1-DT

Other Name(s): SLC20A1 divergent transcript

SLC20A1-DT: A Promising Drug Target Or Biomarker

SLC20A1-DT, or sulfate transporting ATPase 20A subunit, is a protein that is expressed in various tissues and cells throughout the body. It is a member of the ATPase family, which is a diverse group of proteins that are involved in the transfer of ATP energy across various cellular processes. SLC20A1-DT has been identified as a potential drug target or biomarker due to its unique structure and the role it plays in several physiological processes.

SLC20A1-DT is a 20 kDa protein that is expressed in the heart, liver, and kidneys. It is highly conserved, with a calculated pI of 6.3, which makes it a strong candidate for drug targeting. The protein has a unique structure, with a catalytic active site that is separated from the coenzyme active site by a long amino acid tail. This feature allows for the protein to interact with various molecules, including small molecules, ions, and even whole cells, making it a versatile target for drug development.

One of the key functions of SLC20A1-DT is its role in the transfer of ATP energy across various cellular processes. It is a critical enzyme in the production of ATP, which is the primary energy currency of the cell. SLC20A1-DT is involved in the transfer of ATP from the cell pigment c oxidase complex to various cellular organelles, including the cytoplasm, mitochondria, endoplasmic reticulum, and sarcoplasmic reticulum. This process is critical for the delivery of energy to various cellular processes, including muscle contractions, vasodilation, and neurotransmitter release.

SLC20A1-DT has also been shown to play a key role in the regulation of inflammation and fibrosis. fibrosis is a complex process that involves the excessive accumulation of extracellular matrix proteins, such as collagen, in tissues, which can lead to the development of diseases such as cancer, heart disease, and diabetes. SLC20A1-DT has been shown to regulate the activity of several enzymes involved in fibrosis, including the transcription factor, nuclear factor kappa B (NF-kappa-B), and the collagen-producing enzyme, collagenase.

In addition to its role in the transfer of ATP energy and regulation of inflammation and fibrosis, SLC20A1-DT has also been shown to play a key role in the development and progression of certain diseases. for example, SLC20A1-DT has been shown to be involved in the development of cancer, particularly breast cancer. Studies have shown that high levels of SLC20A1-DT are associated with the development of breast cancer, and that inhibition of the protein has been shown to be effective in treating this disease.

Despite its potential as a drug target or biomarker, SLC20A1-DT is still a relatively unstudied protein. There are currently no known drugs that are specifically targeted against SLC20A1-DT, and research is focused on understanding its structure and function, as well as its potential as a drug target or biomarker.

In conclusion, SLC20A1-DT is a unique and promising protein that has the potential to be a drug target or biomarker. Its unique structure and the various functions it is involved in make it an attractive target for drug development. Further research is needed to fully understand its potential and to develop safe and effective drugs that target SLC20A1-DT.

Protein Name: SLC20A1 Divergent Transcript

The "SLC20A1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC20A1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets